Your browser doesn't support javascript.
loading
Treatment of solitary small hepatocellular carcinoma: consideration of hepatic functional reserve and mode of recurrence.
Horigome, H; Nomura, T; Nakao, H; Saso, K; Takahashi, Y; Akita, S; Sobue, S; Mizuno, Y; Nojiri, S; Hirose, A; Masuko, K; Murasaki, G; Fujino, N; Nakahara, R; Ichikawa, T; Itoh, M.
Afiliação
  • Horigome H; First Department of Internal Medicine, Nagoya City University Medical School, Japan.
Hepatogastroenterology ; 47(32): 507-11, 2000.
Article em En | MEDLINE | ID: mdl-10791223
ABSTRACT
BACKGROUND/

AIMS:

Hepatocellular carcinoma (HCC) recurs frequently after initial treatment. The subsequent prognosis varies with the mode of recurrence. Some patients die of hepatic failure even though the HCC is controlled. We consider the clinical stage (CS), using the modified Child-Pugh classification, to be an important factor influencing the prognosis of these patients.

METHODOLOGY:

To determine the most effective treatment for HCC, we examined 105 patients with solitary small HCC who were followed-up for more than 1 year after initial treatment. All of them were judged to be cured according to imaging or histological studies. The initial treatments were hepatic resection (n = 43), percutaneous ethanol injection therapy (PEIT, n = 33), and percutaneous microwave coagulation therapy (PMCT, n = 29). The modes of recurrence were divided into intrahepatic metastasis (IM) and multicentric occurrence (MO).

RESULTS:

Prognosis of MO was superior to that of IM in CS I patients, but there was no difference in prognosis between these modes in CS II. The hepatic resection group had more MO recurrences in CS I patients and more IM recurrences in CS II patients. IM developed frequently after PEIT and PMCT, regardless of the CS. Prognosis with hepatic resection was superior to that of the other treatments in CS I patients, but there was no difference in prognosis among the 3 treatment modalities in CS II patients.

CONCLUSIONS:

These data indicate that hepatic resection is the first choice for treating HCC in CS I patients, and that PEIT or PMCT is preferable for CS II patients.
Assuntos
Buscar no Google
Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles / 7_ODS3_muertes_prevenibles_nacidos_ninos Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Hepatectomia / Testes de Função Hepática / Neoplasias Hepáticas / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Hepatogastroenterology Ano de publicação: 2000 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles / 7_ODS3_muertes_prevenibles_nacidos_ninos Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Hepatectomia / Testes de Função Hepática / Neoplasias Hepáticas / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Hepatogastroenterology Ano de publicação: 2000 Tipo de documento: Article